Valtech Cardio, Ltd. Agrees to be Acquired by Edwards Lifesciences

Or Yehuda, Israel (ots/PRNewswire) -

Transaction Provides Opportunity to Optimize the Significant
Potential of the Cardioband[TM] Heart Valve Repair System

Valtech Cardio, Ltd. (http://www.valtechcardio.com/), (Valtech),
an innovator in the field of device development for mitral and
tricuspid valve repair and replacement, today announced agreement to
be acquired by Edwards Lifesciences Corporation (Edwards). The
acquisition will give Edwards access to the Cardioband[TM]
Reconstruction System (Cardioband) for transcatheter repair of the
mitral valve and tricuspid valve of the heart.

(Logo: http://photos.prnewswire.com/prnh/20160913/407099LOGO )

"We are pleased that Edwards, a global leader in patient focused
medical innovations for structural heart disease, has elected to
include in its growing portfolio of transcatheter based therapies,
the Cardioband[TM] system for both mitral and tricuspid valve repair.
We believe this will position Cardioband[TM] to achieve its full
potential as a fundamental breakthrough in the way patients are
treated for both mitral and tricuspid regurgitation" said Amir Gross,
Founder and CEO of Valtech. "On behalf of the entire Valtech
organization, I want to thank the many physicians who supported us
over the past ten years in the development of the Cardioband[TM]
platform."

"None of our success with the Cardioband[TM] program could have
been achieved without the passion and perseverance of the entire
Valtech team. We are extremely proud of their accomplishments over
the past ten years, and are very excited about the potential impact
Cardioband[TM] will have on patient care in the years ahead," said
Lawrence Best, Executive Chairman of Valtech.

About Valtech's Products

Cardioband[TM] Mitral Reconstruction System

Cardioband[TM] received CE Mark certification in September 2015
after demonstrating safety in a clinical trial among patients with
functional mitral regurgitation. Cardioband[TM] permits physicians to
repair the mitral valve in a first-line setting while preserving the
option to perform future percutaneous or surgical valve repair and/or
replacement.

Cardioband[TM] combines a reconstruction implant, similar to
surgical annuloplasty devices, with a transcatheter transseptal
delivery system. Connection of the implant to the mitral annulus is
sutureless, using specially designed anchors. Reshaping of the mitral
annulus to eliminate FMR is done under physiological conditions and
echocardiographic guidance for optimal results.

Cardioband[TM] Tricuspid Reconstruction System

Cardioband[TM] TR is designed to enable physicians to reconstruct
the tricuspid valve using the same technique and implant as the
Cardioband[TM] mitral valve repair technology. The company is
recruiting patients for its CE study in Europe.

Cardiovalve[TM] Replacement System

Prior to the closing, Valtech will spin out its early stage
Cardiovalve[TM] program, and as part of the agreement, Edwards will
retain an option to acquire the Cardiovalve[TM] program at a later
date. Cardiovalve[TM] is a transcatheter, transseptally delivered,
low-profile, mitral valve replacement (TMVR) system following the
Valtech way of delivering surgical based solutions without the risk
of surgery. The Cardiovalve[TM] platform has an
orientation-indifferent structure for reduced implant complexity and
was designed from inception to enable transseptal delivery.

About Valtech Cardio, Ltd.

Valtech Cardio, Ltd., founded in 2005, is a privately held company
specializing in the development of devices for mitral and tricuspid
valve repair and replacement. Aside from Cardioband[TM], Valtech's
portfolio includes a surgical valve repair portfolio and a
transcatheter valve replacement, Cardiovalve[TM], in development.
Valtech has full in-house development, manufacturing and clinical
research capabilities, as well as over 150 patents and patent
applications. Valtech is headquartered with R&D facility in Or
Yehuda, Israel. For more information visit the Company's website:
http://www.valtechcardio.com.

Contact

Amir Gross

Valtech Cardio

amir@valtechcardio.com

ots Originaltext: Valtech Cardio, Ltd.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
(+972)-54-2233227

Original-Content von: Valtech Cardio, Ltd., übermittelt durch news aktuell